Beate Schmöele-Thoma

Author

Also Known As

B Schmöle-Thoma, B. Schmoele-Thoma, B. Schmöele‐Thoma, Beate Schmoele-Thoma, Beate Schmöele-Thoma, Beate Schmöle-Thoma, Schmoele-Thoma B, Vivek Shinde

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Pfizer (Germany)Pfizer (United States)Pfizer (United Kingdom)University of Rochester Medical Center Cincinnati Children's Hospital Medical Center

About

Beate Schmöele-Thoma is an author at Pfizer (Germany) specializing in medicine, vaccination, and vaccinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	545
2	Immunology	10	10	514
3	Public Health	2	2	66
4	Epidemiology	2	2	77
5	Clinical Effectiveness	1	1	31

Beate Schmöele-Thoma

Publications

Citations

H-Index

Page 1

	Year	Citations
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults Marc J. M. Bonten, Susanne M. Huijts, Marieke Bolkenbaas, New England Journal of Medicine	2015	1.2K
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults Edward E. Walsh, Gonzalo Pérez Marc, Agnieszka Zareba, New England Journal of Medicine	2023	574
Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory A de Roux, Beate Schmöele-Thoma, George R. Siber, Clinical Infectious Diseases	2008	263
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, Vaccine	2013	230
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Vaccine	2013	186
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, Vaccine	2013	162
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age Richard N. Greenberg, Alejandra Gurtman, Robert W. Frenck, Vaccine VaccinologyVaccine SafetyVaccinationVaccine DevelopmentMedicine	2014	157
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study Beate Schmöele-Thoma, Agnieszka Zareba, Qin Jiang, New England Journal of Medicine	2022	139
Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study Catherine Cordonnier, Per Ljungman, Christine Juergens, Clinical Infectious Diseases	2015	102
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine Edward E. Walsh, Ann R. Falsey, Daniel A. Scott, The Journal of Infectious Diseases	2021	100

Page 1